CSL Annual Report 2022

CSL Limited Annual Report 2021/22 13 Operating Review CSL Behring Total revenue was US$8,598 million, up 2%1 when compared to the prior comparable period. Immunoglobulin (Ig) product sales of US$4,024 million, were down 3%1 as supply was constrained by the lower plasma collected in the previous year. Despite the challenging environment, HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were steady due to the preference for home administration and the continued uptake for HIZENTRA® for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a debilitating neurological disorder. PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) declined modestly, impacted by supply constraints and the patient preference for HIZENTRA®. Underlying demand for Ig continues to be robust due to significant patient needs in core indications – namely Primary Immune Deficiency, Secondary Immune Deficiency and CIDP. Specialty product sales of US$1,792 million, up 3%1 led predominately by demand for KCENTRA® and to a lesser extent HAEGARDA®. KCENTRA® (4 factor prothrombin complex concentrate) recorded sales growth of 18%1, as hospital demand for the product returned to pre-pandemic levels driven by penetration within large hospitals and expansion into smaller regional accounts. HAEGARDA®, a therapy for patients with hereditary angioedema, grew by 5%1, driven by continued patient growth and a continued shift from on-demand to prophylaxis treatment. New launches in Europe and Australia have contributed to the rise in patient numbers. Growth in the specialty portfolio was offset by lower wound healing product sales in Japan and a decline in ZEMAIRA® (alpha-1-proteinase inhibitor) following supply interruptions at our Kankakee facility in the US. Haemophilia product sales of US$1,166 million increased 8%1. IDELVION®, CSL Behring’s novel long-acting recombinant factor IX product, achieved strong growth of 20%1 driven by its clinical profile that continues to attract patient demand and gain market share. It remains the market leader for the treatment of haemophilia B patients. The haemophilia A market has been competitive resulting in sales declines for AFSTYLA®, a novel recombinant factor VIII product, and plasma-derived products. Albumin sales of US$1,072 million, were down 1%1. Sales in China were up strongly whereas sales in other major market such as the US and Europe declined modestly due to the supply constraints from the lower plasma collections in the previous year. Plasma collections Whilst plasma collections were adversely impacted by the COVID-19 pandemic in the previous financial year, this year saw strong growth with plasma volumes collected up 24%. This was the result of targeted marketing efforts and enhanced digital initiatives to attract donors. The cost of collections also increased including donor compensation and labour. CSL Seqirus Total revenue of $1,964 million, was up 13%1 driven by growth in seasonal influenza vaccines and CSL Seqirus’ differentiated high value products, in particular FLUAD®, the adjuvanted product for the elderly market. 1 Constant Currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior comparable period (Translation Currency Effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior comparable period (Transaction Currency Effect); and c) by adjusting for current year foreign currency gains and losses (Foreign Currency Effect). The sum of translation currency effect, transaction currency effect and foreign currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.